 This research has identified a new LNCRNA, called LNCFSD2311, which is associated with longer survival times in pancreatic cancer patients. The LNCRNA is secreted from cancer cells into the surrounding environment, where it binds to extracellular vesicles, EVs. These EVs then carry the LNCRNA to nearby cancer-associated fibroblasts, CAFs, where they can activate them. In turn, these activated CAFs can promote the growth of the cancer cells. By blocking the LNCRNA's ability to interact with the EVs, the researchers were able to reduce the growth of the cancer cells in mice. This suggests that LNCFSD2311 could potentially be used as a biomarker or therapeutic target for pancreatic cancer. This article was authored by Shinglong Geng, Lulie, Yen Luo, and others.